Document is current
Any future updates will be listed below
-
Authors
Jeyakumar, Jey M. https://orcid.org/0000-0002-6884-8804
Kia, Azadeh
Tam, Lawrence C. S.
McIntosh, Jenny https://orcid.org/0000-0003-4115-7867
Spiewak, Justyna
Mills, Kevin
Heywood, Wendy
Chisari, Elisa
Castaldo, Noemi
Verhoef, Daniël
Hosseini, Paniz
Kalcheva, Petya
Cocita, Clement
Miranda, Carlos J.
Canavese, Miriam
Khinder, Jaminder
Rosales, Cecilia
Hughes, Derralynn
Sheridan, Rose
Corbau, Romuald
Nathwani, Amit
- License Information
-
More Information
Article History
Received: 4 May 2022
Revised: 6 December 2022
Accepted: 21 December 2022
First Online: 11 January 2023
Competing interests
: JJ, AK, LT, EC, NC, DV, PH, PK, CC, CM, MC, JK, RS, RC are employees and/or shareholders of Freeline Therapeutics. AN is a Director, shareholder, and holds patents with Freeline Therapeutics. DH: Advisory Boards: Freeline Therapeutics, Sanofi, Takeda, Amicus, Idorsia; Consulting Fees: Freeline Therapeutics, Sanofi, Takeda, Amicus, Idorsia, Protalix, Sangamo; Honoraria: Freeline Therapeutics, Sanofi, Takeda, Amicus, Idorsia. The other authors declare no competing interests.
